CellaVision ABCVLLY +12.06%69 ROE % is 9.98% as of Mar. 2026, which is 59% below its 10-year median of 24.39. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 799 Medical Devices & Instruments companies, CellaVision AB ranks better than 85.98% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CellaVision AB's annualized net income for the quarter that ended in Mar. 2026 was $9.66 Mil. CellaVision AB's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $96.82 Mil. Therefore, CellaVision AB's annualized ROE % for the quarter that ended in Mar. 2026 was 9.98%.
The historical rank and industry rank for CellaVision AB's ROE % or its related term are showing as below:
CVLLY'
s ROE % Range Over the Past 10 Years
Min: 15.54 Med: 24.39 Max: 33.39
Current: 15.54
During the past 13 years, CellaVision AB's highest ROE % was 33.39%. The lowest was 15.54%. And the median was 24.39%.
CVLLY's ROE % is ranked better than 85.98% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs CVLLY: 15.54
CellaVision AB (OTCPK:CVLLY) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
CellaVision AB ROE % Related Terms
CellaVision AB ROE % Historical Data
* Premium members only.
The historical data trend for CellaVision AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's ROE % distribution charts can be found below:
* The bar in red indicates where CellaVision AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
CellaVision AB (CVLLY) has a ROE % of 9.98% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CellaVision AB and its competitors. This is 59% below median its historical median of 24.39. Over the past decade, CellaVision AB's ROE % has ranged from 15.54 to 33.39. According to the industry distribution chart, CellaVision AB ranks #112 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 14%.
Is CellaVision AB's ROE % too high?
CellaVision AB's current ROE % of 9.98% is 59% below median its 10-year median of 24.39. Over the past 10 years, this metric has ranged from a low of 15.54 to a high of 33.39. The Medical Devices & Instruments industry median ROE % is 2.42. CellaVision AB's value of 9.98% is 312.4% above this industry median. Based on the distribution chart, CellaVision AB ranks #112 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #112 out of 799 companies for ROE %. This places CellaVision AB in the top 14% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. CellaVision AB's value of 9.98% is 312.4% above this benchmark. Historically, CellaVision AB's own ROE % has ranged from 15.54 to 33.39 over the past decade. While the company's 10-year median is 24.39 vs. the industry median of 2.42, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current ROE % of 9.98% is 312.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current ROE % is 9.98%, which is 59% below median its own 10-year median of 24.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current ROE % is 9.98%, which is 59% below median its 10-year median of 24.39 and 312.4% above the Medical Devices & Instruments industry median of 2.42. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current ROE % is 9.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
ROE %: 9.98% (59% below median its 10-year median of 24.39)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 312.4% above the Medical Devices & Instruments median (#112 of 799)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
